(Institución)/></a>
				</td>
				<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Oncología > Oncología molecular > DA - CIMA - Oncología - Oncología molecular - Artículos de Revista >

New symmetrical quinazoline derivatives selectively induce apoptosis in human cancer cells
Autor(es) : Cubedo, E. (Elena)
Cordeu, L. (Lucía)
Bandres, E. (Eva)
Rebollo, A. (Amaia)
Malumbres, R. (Raquel)
Sanmartin-Grijalba, C. (Carmen)
Font, M. (María)
Palop-Cubillo, J.A. (Juan Antonio)
Garcia-Foncillas, J. (Jesús)
Palabras clave : Apoptosis induction
Quinazoline derivatives
Fecha incorporación: 2006
Editorial : Landes Bioscience
Versión del editor: http://www.landesbioscience.com/journals/cbt/article/2841/
ISSN: 1555-8576
Cita: Cubedo E, Cordeu L, Bandres E, Rebollo A, Malumbres R, Sanmartin C, et al. New symmetrical quinazoline derivatives selectively induce apoptosis in human cancer cells. Cancer Biol Ther 2006 Jul;5(7):850-859.
Resumen
In the search of new symmetrical derivatives with anticancer activity, we have looked for novel compounds able to induce a selective proapoptotic mechanism in cancer cells. The potential antitumoral activity of several quinazoline derivatives was evaluated in vitro examining their cytotoxic effects against human breast, colon and bladder cancer cell lines. The IC(50) value of the compounds that showed cytotoxic activity was calculated. These compounds were tested for their ability to induce caspase-3 activation and nuclear chromatin degradation. Non-tumoral human cell lines were used to test the selectivity of the cytotoxic compounds against cancer cells. Several compounds showed no cytotoxicity in these cell lines. Finally, JRF12 (2,4-dibenzylaminoquinazoline) was chosen as the best candidate and its mechanism of action was studied in more detail. A time dependent evaluation of apoptosis was performed in the three cancer cell lines, followed by an evaluation of the cell cycle regulation involvement that showed a decrease of cells in G(1) phase and increase of cells in G(2) phase before cell death. 2,4-dibenzylaminoquinazoline treatment produces few changes in the expression of genes as evaluated by using oligonucleotide microarrays and Q-RT-PCR assays. In conclusion, 2,4-dibenzylaminoquinazoline is a promising anticancer drug showing cytostatic and apoptotic effects mainly in a transcription independent manner.
Enlace permanente: http://hdl.handle.net/10171/23045
Aparece en las colecciones: DA - Farmacia - Orgánica - Artículos de revista
DA - CIMA - Oncología - Oncología molecular - Artículos de Revista

Ficheros en este registro:
Fichero:  CancBiolTher2006_5_7_850.pdf
Descripción: 
Tamaño:  719,75 kB
Formato:  Adobe PDF
 Visualizar / Abrir 

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.